Estrogen replacement therapy in breast cancer survivors
Objective: To determine whether estrogen replacement therapy (ERT) adversely affected outcome of breast cancer survivors. Method: A prospective descriptive study of all breast cancer survivors who requested ERT because of intractable menopausal symptoms. All patients presented voluntarily as gynecol...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecology and obstetrics 1999, Vol.64 (1), p.59-63 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63 |
|---|---|
| container_issue | 1 |
| container_start_page | 59 |
| container_title | International journal of gynecology and obstetrics |
| container_volume | 64 |
| creator | Guidozzi, F |
| description | Objective: To determine whether estrogen replacement therapy (ERT) adversely affected outcome of breast cancer survivors.
Method: A prospective descriptive study of all breast cancer survivors who requested ERT because of intractable menopausal symptoms. All patients presented voluntarily as gynecological outpatients and were all given oral continuous opposed ERT: 20 premarin and medroxyprogesterone and four tibolone.
Results: Twenty-four patients who had previously been treated for breast cancer 8–91 months prior to their initiating ERT have been observed for 24–44 months. There were 15 patients with stage 1, eight with stage 2 and one with stage 4 breast cancer. The mean age of the patients at commencement of ERT was 48 years (range 42–61). Two patients had a biopsy of a suspicious breast nodule: both of which were benign. There have not been any recurrences to date.
Conclusion: Breast cancer survivors did not have their outcome adversely affected by ERT during an observation period of 24–44 months. |
| doi_str_mv | 10.1016/S0020-7292(98)00222-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69666614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0020729298002227</els_id><sourcerecordid>69666614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4409-e5889131a4d96d6f58c1bf702a2ea2e9e142bfaf332464644d241bd5b4a2b2ef3</originalsourceid><addsrcrecordid>eNqNkEFLwzAYhoMobk5_gtKDiB6qSZomzUlkzDkZ7KCeQ5p-1UjXzqSb7N-brUO9aRIIgef9XvIgdErwNcGE3zxhTHEsqKSXMrsKD0pjsYf6JBMyTpiQ-6j_jfTQkffvGGMiCDlEvTBBYi5IH4mRb13zCnXkYFFpA3Oo26h9A6cX68jWUe5A-zYyujbgIr90K7tqnD9GB6WuPJzs7gF6uR89Dx_i6Ww8Gd5NY8MYljGkWSZJQjQrJC94mWaG5KXAVFMIRwJhNC91mSSU8bBZQRnJizRnmuYUymSALrq5C9d8LMG3am69garSNTRLr7jkYREWwLQDjWu8d1CqhbNz7daKYLUxprbG1EaHkpnaGlMi5M52Bct8DsWvVKcoAOc7QHujq9IFE9b_cDzjybZfdtinrWD9v3I1eRzPUhmyt10WgsmVBae8sRCEF9aBaVXR2D9-8QVm9JfM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69666614</pqid></control><display><type>article</type><title>Estrogen replacement therapy in breast cancer survivors</title><source>MEDLINE</source><source>Wiley Journals</source><source>Access via ScienceDirect (Elsevier)</source><creator>Guidozzi, F</creator><creatorcontrib>Guidozzi, F</creatorcontrib><description>Objective: To determine whether estrogen replacement therapy (ERT) adversely affected outcome of breast cancer survivors.
Method: A prospective descriptive study of all breast cancer survivors who requested ERT because of intractable menopausal symptoms. All patients presented voluntarily as gynecological outpatients and were all given oral continuous opposed ERT: 20 premarin and medroxyprogesterone and four tibolone.
Results: Twenty-four patients who had previously been treated for breast cancer 8–91 months prior to their initiating ERT have been observed for 24–44 months. There were 15 patients with stage 1, eight with stage 2 and one with stage 4 breast cancer. The mean age of the patients at commencement of ERT was 48 years (range 42–61). Two patients had a biopsy of a suspicious breast nodule: both of which were benign. There have not been any recurrences to date.
Conclusion: Breast cancer survivors did not have their outcome adversely affected by ERT during an observation period of 24–44 months.</description><identifier>ISSN: 0020-7292</identifier><identifier>EISSN: 1879-3479</identifier><identifier>DOI: 10.1016/S0020-7292(98)00222-7</identifier><identifier>PMID: 10190671</identifier><identifier>CODEN: IJGOAL</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Biological and medical sciences ; Breast cancer survivors ; Breast Neoplasms - pathology ; Drug toxicity and drugs side effects treatment ; Estrogen Replacement Therapy ; Estrogen therapy ; Female ; Humans ; Medical sciences ; Menopause ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Neoplasm Recurrence, Local - epidemiology ; Pharmacology. Drug treatments ; Prospective Studies ; Retrospective Studies ; Survivors</subject><ispartof>International journal of gynecology and obstetrics, 1999, Vol.64 (1), p.59-63</ispartof><rights>1999 International Federation of Gynecology and Obstetrics</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4409-e5889131a4d96d6f58c1bf702a2ea2e9e142bfaf332464644d241bd5b4a2b2ef3</citedby><cites>FETCH-LOGICAL-c4409-e5889131a4d96d6f58c1bf702a2ea2e9e142bfaf332464644d241bd5b4a2b2ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2FS0020-7292%2898%2900222-7$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0020-7292(98)00222-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,1417,3550,4024,27923,27924,27925,45574,45575,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1686314$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10190671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guidozzi, F</creatorcontrib><title>Estrogen replacement therapy in breast cancer survivors</title><title>International journal of gynecology and obstetrics</title><addtitle>Int J Gynaecol Obstet</addtitle><description>Objective: To determine whether estrogen replacement therapy (ERT) adversely affected outcome of breast cancer survivors.
Method: A prospective descriptive study of all breast cancer survivors who requested ERT because of intractable menopausal symptoms. All patients presented voluntarily as gynecological outpatients and were all given oral continuous opposed ERT: 20 premarin and medroxyprogesterone and four tibolone.
Results: Twenty-four patients who had previously been treated for breast cancer 8–91 months prior to their initiating ERT have been observed for 24–44 months. There were 15 patients with stage 1, eight with stage 2 and one with stage 4 breast cancer. The mean age of the patients at commencement of ERT was 48 years (range 42–61). Two patients had a biopsy of a suspicious breast nodule: both of which were benign. There have not been any recurrences to date.
Conclusion: Breast cancer survivors did not have their outcome adversely affected by ERT during an observation period of 24–44 months.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Breast cancer survivors</subject><subject>Breast Neoplasms - pathology</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Estrogen Replacement Therapy</subject><subject>Estrogen therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Survivors</subject><issn>0020-7292</issn><issn>1879-3479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEFLwzAYhoMobk5_gtKDiB6qSZomzUlkzDkZ7KCeQ5p-1UjXzqSb7N-brUO9aRIIgef9XvIgdErwNcGE3zxhTHEsqKSXMrsKD0pjsYf6JBMyTpiQ-6j_jfTQkffvGGMiCDlEvTBBYi5IH4mRb13zCnXkYFFpA3Oo26h9A6cX68jWUe5A-zYyujbgIr90K7tqnD9GB6WuPJzs7gF6uR89Dx_i6Ww8Gd5NY8MYljGkWSZJQjQrJC94mWaG5KXAVFMIRwJhNC91mSSU8bBZQRnJizRnmuYUymSALrq5C9d8LMG3am69garSNTRLr7jkYREWwLQDjWu8d1CqhbNz7daKYLUxprbG1EaHkpnaGlMi5M52Bct8DsWvVKcoAOc7QHujq9IFE9b_cDzjybZfdtinrWD9v3I1eRzPUhmyt10WgsmVBae8sRCEF9aBaVXR2D9-8QVm9JfM</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Guidozzi, F</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>Estrogen replacement therapy in breast cancer survivors</title><author>Guidozzi, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4409-e5889131a4d96d6f58c1bf702a2ea2e9e142bfaf332464644d241bd5b4a2b2ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Breast cancer survivors</topic><topic>Breast Neoplasms - pathology</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Estrogen Replacement Therapy</topic><topic>Estrogen therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Survivors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guidozzi, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guidozzi, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen replacement therapy in breast cancer survivors</atitle><jtitle>International journal of gynecology and obstetrics</jtitle><addtitle>Int J Gynaecol Obstet</addtitle><date>1999</date><risdate>1999</risdate><volume>64</volume><issue>1</issue><spage>59</spage><epage>63</epage><pages>59-63</pages><issn>0020-7292</issn><eissn>1879-3479</eissn><coden>IJGOAL</coden><abstract>Objective: To determine whether estrogen replacement therapy (ERT) adversely affected outcome of breast cancer survivors.
Method: A prospective descriptive study of all breast cancer survivors who requested ERT because of intractable menopausal symptoms. All patients presented voluntarily as gynecological outpatients and were all given oral continuous opposed ERT: 20 premarin and medroxyprogesterone and four tibolone.
Results: Twenty-four patients who had previously been treated for breast cancer 8–91 months prior to their initiating ERT have been observed for 24–44 months. There were 15 patients with stage 1, eight with stage 2 and one with stage 4 breast cancer. The mean age of the patients at commencement of ERT was 48 years (range 42–61). Two patients had a biopsy of a suspicious breast nodule: both of which were benign. There have not been any recurrences to date.
Conclusion: Breast cancer survivors did not have their outcome adversely affected by ERT during an observation period of 24–44 months.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>10190671</pmid><doi>10.1016/S0020-7292(98)00222-7</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7292 |
| ispartof | International journal of gynecology and obstetrics, 1999, Vol.64 (1), p.59-63 |
| issn | 0020-7292 1879-3479 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69666614 |
| source | MEDLINE; Wiley Journals; Access via ScienceDirect (Elsevier) |
| subjects | Adult Biological and medical sciences Breast cancer survivors Breast Neoplasms - pathology Drug toxicity and drugs side effects treatment Estrogen Replacement Therapy Estrogen therapy Female Humans Medical sciences Menopause Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Neoplasm Recurrence, Local - epidemiology Pharmacology. Drug treatments Prospective Studies Retrospective Studies Survivors |
| title | Estrogen replacement therapy in breast cancer survivors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A02%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20replacement%20therapy%20in%20breast%20cancer%20survivors&rft.jtitle=International%20journal%20of%20gynecology%20and%20obstetrics&rft.au=Guidozzi,%20F&rft.date=1999&rft.volume=64&rft.issue=1&rft.spage=59&rft.epage=63&rft.pages=59-63&rft.issn=0020-7292&rft.eissn=1879-3479&rft.coden=IJGOAL&rft_id=info:doi/10.1016/S0020-7292(98)00222-7&rft_dat=%3Cproquest_cross%3E69666614%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69666614&rft_id=info:pmid/10190671&rft_els_id=S0020729298002227&rfr_iscdi=true |